A legislative push to ban direct-to-consumer pharma ads—a practice allowed only in the U.S. and New Zealand—is forcing a high-stakes debate in Washington. The proposed End Prescription Drug Ads Now Act faces significant legal hurdles, but a quieter revolution in patient behavior may already be making the argument moot.
John Cunningham is Chief Commercial Officer at QPharma, a firm specializing in commercial support and HCP engagement for life sciences. He says the focus on advertising misses a much bigger story about how today’s consumers are taking control of their own healthcare journeys.
The patient will see you now: Cunningham argues that the entire debate is lagging behind the reality of how people approach medicine, as consumers are no longer passive recipients of information. “In today’s world, with information on demand and artificial intelligence, a lot of patients are self-diagnosing anyway,” says Cunningham. “They’re going to the Internet, they’re Googling, they’re going to ChatGPT to understand their particular disease state.” This empowerment extends to their wallets; platforms like GoodRx let them research pricing and even become cash patients to cut out payers.
The doctor is out: This advertising boom didn’t happen in a vacuum, but was a direct response to a growing problem for pharma companies. “Over the last number of years, access to HCPs’ offices has been extremely limited,” Cunningham explains. With large healthcare organizations restricting sales rep visits, brands “had to resort to more non-traditional methods, including more direct-to-consumer advertising,” to create a groundswell of interest.
A fuzzy ROI: The effectiveness of those expensive TV spots has always been difficult to prove because of the fragile value chain involved. “So many things have to happen perfectly,” Cunningham admits. “A patient hears about a therapy, they go to their doctor, the doctor needs to agree and write the prescription, and then the patient has to go to the pharmacy, see what their copay is, and decide if it’s worth the investment.”
Six degrees of prescription: With DTC’s future in question, the industry must pivot to a more sophisticated, data-driven strategy. The new approach isn’t about mass marketing, but about surgically precise “influence mapping” delivered through omnichannel marketing. “Brands have to work harder to understand the level of influence a KOL has over their friends and other HCPs that follow their lead,” Cunningham says. “Brand teams really need to understand the access points, whether it’s an email, a tele-detail, or a personal visit.”
Painting with a single brush: This new era demands a tech-forward playbook that leverages deep data to move beyond broad campaigns and work smarter. “The only way you can do that is through data analysis, which includes an analysis of formulary status and understanding the payer landscape from a heat map perspective,” Cunningham states. “You can’t paint the market with a single brush anymore. You have to look at the individual nuances of individual therapeutic classes because each one is dramatically different.”
